Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L-Reference-Cited by-同舟云学术

Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L

Published:2021-10 Issue:10 Volume:16 Page:1745-1752
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Akamatsu Hiroaki,Murakami Haruyasu,Harada Hideyuki,Shimizu Junichi,Hayashi Hidetoshi,Daga Haruko,Hasegawa Yoshikazu,Kim Young Hak,Kato Terufumi,Tokunaga Shoji,Nishimura Yasumasa,Yamamoto Nobuyuki,Nakagawa Kazuhiko

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer;Furuse;J Clin Oncol,1999

2. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N Engl J Med,2017

3. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N Engl J Med,2018

4. Role of consolidation durvalumab in patients with EGFR- and HER2- mutant unresectable stage III NSCLC;Hellyer;J Thorac Oncol,2021

5. Durvalumab for Stage III EGFR-mutated NSCLC after definitive chemoradiotherapy;Aredo;J Thorac Oncol,2021

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario;Current Oncology;2024-08-30

2. Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC;New England Journal of Medicine;2024-08-15

3. Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A systematic review and single-arm meta-analysis;PLOS ONE;2024-06-12

4. Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study;Cancer Medicine;2024-04

5. Radiotherapy combined with EGFR-TKIs for stage III EGFR-Mutated lung cancer: A retrospective cohort study;2024-03-15